admin

  Pleasanton, CA and Seoul, South Korea – April 23, 2018 CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, and CrystalGenomics, Inc., (KOSDAQ:083790), a Korea-based biopharmaceutical company with drug discovery, development and commercialization capabilities, today announced a co-development agreement for an investigational

Pleasanton, CA – April 17, 2018 – CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, presented preclinical in-vivo data and animal safety pharmacology studies of CBT-102, a multi-targeted kinase inhibitor with anti-cancer, anti-angiogenic and apoptotic activities targeting VEGFR, PDGFR, MAPK,

Pleasanton, CA – March 22, 2018 CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, announced today a strategic licensing agreement with Crown Bioscience, Inc. The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human

Pleasanton, CA – March 14, 2018 CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced that the company will present at two upcoming investor conferences: March 23, 2018 – Future Leaders in the Biotech Industry at 2:45 –

Pleasanton, CA – October 30, 2017 – CBT Pharmaceuticals (CBT), a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer, presented preclinical data demonstrating the safety and efficacy of its Programmed Death-Ligand 1 (PD-L1) antibody, CBT-502 (TQB2450), in stimulating IL-2 and Interferon gamma production,

Pleasanton, CA – September 28, 2017 – CBT Pharmaceuticals (CBT), a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer, today announced that the first subject has been dosed in the Phase 1 multi-center study, CBT-101-01. CBT-101 is a specific oral inhibitor of the

Pleasanton, CA – August 28, 2017 – CBT Pharmaceuticals (CBT), a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer, today announced the appointments of Robert A. Figlin, MD, FACP and Frank McCormick, PhD, FRS, DSc. to its newly established Scientific Advisory Board (SAB).